- Home
- STGW vs ABVX Comparison
STGW vs ABVX Comparison
Compare STGW & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STGW
- ABVX
- Stock Information
- Founded
- STGW 1980
- ABVX 2013
- Country
- STGW United States
- ABVX France
- Employees
- STGW N/A
- ABVX N/A
- Industry
- STGW
- ABVX
- Sector
- STGW
- ABVX
- Exchange
- STGW Nasdaq
- ABVX Nasdaq
- Market Cap
- STGW 814.3M
- ABVX 722.3M
- IPO Year
- STGW N/A
- ABVX N/A
- Fundamental
- Price
- STGW $6.82
- ABVX $7.65
- Analyst Decision
- STGW Strong Buy
- ABVX Strong Buy
- Analyst Count
- STGW 5
- ABVX 6
- Target Price
- STGW $8.50
- ABVX $38.67
- AVG Volume (30 Days)
- STGW 434.5K
- ABVX 132.7K
- Earning Date
- STGW 11-07-2024
- ABVX 09-09-2024
- Dividend Yield
- STGW N/A
- ABVX N/A
- EPS Growth
- STGW N/A
- ABVX N/A
- EPS
- STGW 0.00
- ABVX N/A
- Revenue
- STGW $2,707,403,000.00
- ABVX $9,676,417.00
- Revenue This Year
- STGW $13.05
- ABVX $31.67
- Revenue Next Year
- STGW N/A
- ABVX $1,189.66
- P/E Ratio
- STGW $5,790.36
- ABVX N/A
- Revenue Growth
- STGW 4.92
- ABVX 100.87
- 52 Week Low
- STGW $4.88
- ABVX $7.11
- 52 Week High
- STGW $8.18
- ABVX $17.02
- Technical
- Relative Strength Index (RSI)
- STGW 32.57
- ABVX 37.23
- Support Level
- STGW $7.32
- ABVX $7.49
- Resistance Level
- STGW $7.40
- ABVX $8.18
- Average True Range (ATR)
- STGW 0.27
- ABVX 0.46
- MACD
- STGW -0.13
- ABVX 0.00
- Stochastic Oscillator
- STGW 6.52
- ABVX 28.27
About STGW Stagwell Inc.
Stagwell Inc is the challenger holding company built to transform marketing. It delivers scaled creative performance for the world's ambitious brands, connecting culture-moving creativity with a technology to harmonize the art and science of marketing. The company's segments include Integrated Agencies Network; Brand Performance Network; Communications Network and other. It generates maximum revenue from the Integrated Agencies Network segment. Geographically, it derives a majority of its revenue from the United States.
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. They are evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two most common forms are UC and CD.